beta-(5-hydroxy-2-pyridyl)alanine has been researched along with bucladesine in 1 studies
| Studies (beta-(5-hydroxy-2-pyridyl)alanine) | Trials (beta-(5-hydroxy-2-pyridyl)alanine) | Recent Studies (post-2010) (beta-(5-hydroxy-2-pyridyl)alanine) | Studies (bucladesine) | Trials (bucladesine) | Recent Studies (post-2010) (bucladesine) |
|---|---|---|---|---|---|
| 31 | 0 | 5 | 9,775 | 13 | 210 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita-Yoshigaki, J; Nishimura, S; Shindo-Okada, N; Yokoyama, S | 1 |
1 other study(ies) available for beta-(5-hydroxy-2-pyridyl)alanine and bucladesine
| Article | Year |
|---|---|
Azatyrosine inhibits neurite outgrowth of PC12 cells induced by oncogenic Ras.
Topics: Alanine; Animals; Antibiotics, Antineoplastic; Bucladesine; Cell Differentiation; Genes, ras; Microinjections; Nerve Growth Factors; Neurites; Oncogene Protein p21(ras); PC12 Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-raf | 1992 |